Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Treatment of Lichen Planopilaris
Description
In this presentation on the treatment of Lichen Planopilaris (LPP), the speaker discusses the condition characterized by scarring alopecia primarily affecting middle-aged women, with an unclear pathogenesis likely influenced by immune dysfunction, genetics, and environmental factors. Patients often experience symptoms such as itching and burning on the scalp. Treatment objectives include reducing hair loss, controlling symptoms, and halting the scarring process, with no expectation of complete regrowth. First-line treatments generally include topical clobetasol and hydroxychloroquine, with response rates around 50-60%. Intralesional steroids can also be utilized, with higher response rates when combined with other therapies. The talk covers various therapeutic options including corticosteroids, doxycycline, methotrexate, and second-line agents like cyclosporine and pioglitazone, emphasizing their response rates and potential side effects. New treatments such as JAK inhibitors show promise but require further study. The complexity of LPP treatment is highlighted by the lack of standardized approaches and the necessity of monitoring disease progression through subjective and objective measures. The speaker notes the importance of early diagnosis and treatment to maintain hair health and quality of life.
View moreConclusions
- Lichen planopilaris (LPP) is characterized by permanent follicle destruction and primarily affects middle-aged women.
- The pathogenesis of LPP remains unclear, with multiple factors potentially contributing.
- Treatment objectives for LPP focus on reducing hair loss, controlling symptoms, and stopping the scarring process.
- Regrowth is not expected since complete inflammation elimination is unlikely.
- Current therapeutic approaches rely on perceived severity due to a lack of consistent progress markers.
- Topical clobetasol and hydroxychloroquine are first-line agents, with response rates around 50-60%.
- Systemic treatments like methotrexate and cyclosporine may be effective but can have significant side effects and high relapse rates.
- JAK inhibitors show promise in more persistent LPP cases but require careful monitoring for side effects such as immunosuppression.
- No standard therapeutic approach exists for LPP, making treatment challenging and variable.
- Early diagnosis and management are crucial in preserving hair and improving patients' quality of life.
- Bolduc C, et al. JAAD. 2017
- Senna MM, et al. JID Innov. 2022
- Christensen KN, et al. Pediatr Dermatol. 2015
- Xie F, Lehman JS. Mayo Clin Proc. 2022
- Naeini FF, et al. Indian J Dermatol Venereol Leprol. 2021
- Errichetti E, et al. Clin Cosmet Investig Dermatol. 2018
- Bolanca Z, et al. Dermatol Ther. 2016
- Jha AK. JAAD. 2018
- Svigos K, et al. JAAD. 2020
- Nichonncha E, et al. Dermatol Ther. 2017
- Chiang C, et al. JAAD. 2010
- Spencer LA, et al. Arch Dermatol. 2009
- Stege H, et al. J Clin Med. 2024
- Cevasco NC, et al. JAAD. 2020
- Doche I, et al. Clin Exp Dermatol. 2018
- Goodarzi M, et al. Arch Iran Med. 2025
- Li Z, et al. Dermatol Ther. 2022
- Plante J, et al. JAAD. 2020
- Batra P, et al. SAD. 2020
- Moussa A, et al. JAAD. 2022
- Lee JA, et al. Laryngoscope. 2021
- Pathoulas JT, et al. JAAD. 2022
- Peterson EL, et al. J Drugs Dermatol. 2019
- Mostafa N, et al. J Dermatol Treat. 2020
- Diab R, et al. Dermatol Ther. 2022
- Svigos K, et al. Am J Clin Dermatol. 2021